Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Evinacumab-dgnb (Evkeeza) serves as an adjunct to other low-density lipoprotein-cholesterol (LDL-C) lowering therapies for adult and pediatric patients, aged 5 years and older, with homozygous familial hypercholesterolemia.
• The information was sourced from two studies that focused on the efficacy and safety of Evkeeza compared to other lipid-lowering treatments.
• Evinacumab-dgnb significantly reduces LDL-C by a mean difference (MD) of -33.123%, triglycerides by MD -50.959%, and high-density lipoprotein cholesterol (HDL-C) by MD -12.773% when compared to placebo, according to the meta-analysis results from five randomized controlled trials involving 568 participants.
• In terms of safety, there were no significant differences between groups treated with evinacumab-dgnb versus placebo groups in incidence rates of treatment-emergent adverse events such as nasopharyngitis, influenza-like illness, headache, and dizziness, indicating a favorable safety profile for Evkeeza.
• Compared indirectly with statins like alirocumab or evolocumab, which target lipid metabolism at various biological levels, evinacumab-dgnb uniquely inhibits angiopoietin-like protein 3, contributing to advancements in homozygous familial hypercholesterolemia treatments.
• The studies suggest broad applicability across diverse patient populations within the specified indication domain, highlighting the drug's utility in not only adults but also younger patients suffering from homozygous familial hypercholesterolemia.